PVA/κ-carrageenan/Au/camptothecin/pegylated-polyurethane/paclitaxel nanofibers against lung cancer treatment

Irani, Mohammad; Nodeh, Sina Mohammadrezaei

doi:10.1039/d2ra02150a

Cited by 10 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recognizing the limitations of monotherapy, the development of dual-drug combinations has developed as a promising strategy to enhance therapeutic efficacy (Li, Liu, & Abdelhakim, 2022). However, the success of this dual-drug therapy approach is contingent upon appropriate dosage selection, as an imbalance in drug concentrations may prevent treatment effectiveness and potentially produce adverse effects (Irani & Nodeh, 2022). To address this challenge, Shen's group fabricated two-chamber core-shell nanofibers with a dual-drug payload, in which the Chinese medicine Ganoderma lucidum triterpenoids (GLT) and Western medicine methotrexate (MTX) were stored in the two distinct layers, respectively (Shen et al, 2020).…”

Section: Targeted Drug Delivery Systemsmentioning

confidence: 99%

Electrospun multi‐chamber core–shell nanofibers and their controlled release behaviors: A review

Liu,

Chen,

Lin

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Core–shell structure is a concentric circle structure found in nature. The rapid development of electrospinning technology provides more approaches for the production of core–shell nanofibers. The nanoscale effects and expansive specific surface area of core–shell nanofibers can facilitate the dissolution of drugs. By employing ingenious structural designs and judicious polymer selection, specialized nanofiber drug delivery systems can be prepared to achieve controlled drug release. The synergistic combination of core–shell structure and materials exhibits a strong strategy for enhancing the drug utilization efficiency and customizing the release profile of drugs. Consequently, multi‐chamber core–shell nanofibers hold great promise for highly efficient disease treatment. However, little attention concentration is focused on the effect of multi‐chamber core–shell nanofibers on controlled release of drugs. In this review, we introduced different fabrication techniques for multi‐chamber core–shell nanostructures, including advanced electrospinning technologies and surface functionalization. Subsequently, we reviewed the different controlled drug release behaviors of multi‐chamber core–shell nanofibers and their potential needs for disease treatment. The comprehensive elucidation of controlled release behaviors based on electrospun multi‐chamber core–shell nanostructures could inspire the exploration of novel controlled delivery systems. Furthermore, once these fibers with customizable drug release profiles move toward industrial mass production, they will potentially promote the development of pharmacy and the treatment of various diseases.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Section: Targeted Drug Delivery Systemsmentioning

confidence: 99%

Electrospun multi‐chamber core–shell nanofibers and their controlled release behaviors: A review

Liu,

Chen,

Lin

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…PTX combined with camptothecin (CPT) has several advantages over monotherapy. The co-delivery of PTX and CPT has better treatment efficacy for cancer therapy compared to monotherapy [ 95 ]. PTX and CPT couple to ionizable amino lipids to form polysaccharide amino acid lipids (PAL).…”

Section: Clinical Implications Of Slns In Breast Cancer Therapymentioning

confidence: 99%

Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy

Mo,

Kim,

Choe

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs), composed of ionized lipids, helper lipids, and cholesterol, provide general therapeutic effects by facilitating intracellular transport and avoiding endosomal compartments. LNP-based drug delivery has great potential for the development of novel gene therapies and effective vaccines. Solid lipid nanoparticles (SLNs) are derived from physiologically acceptable lipid components and remain robust at body temperature, thereby providing high structural stability and biocompatibility. By enhancing drug delivery through blood vessels, SLNs have been used to improve the efficacy of cancer treatments. Breast cancer, the most common malignancy in women, has a declining mortality rate but remains incurable. Recently, as an anticancer drug delivery system, SLNs have been widely used in breast cancer, improving the therapeutic efficacy of drugs. In this review, we discuss the latest advances of SLNs for breast cancer treatment and their potential in clinical use.

show abstract

“…The core‐sheath nanostructures developed by coaxial electrospinning are ideal carriers for drug delivery systems (DDSs). The large specific surface area, low cost, high drug loading efficiency, and drug release in a controlled manner are favorable characteristics of core‐shell nanofibers for DDSs 9–16 . Electrospun core‐sheath nanofibers have been demonstrated to be potential candidates for providing various drug controlled release profiles, particularly drug sustained release resulted from the elaborate tailoring of sheath and core components 17–19 .…”

Section: Introductionmentioning

confidence: 99%

Fabrication of poly(ϵ‐caprolactone)/paclitaxel (core)/chitosan/zein/multi‐walled carbon nanotubes/doxorubicin (shell) nanofibers against MCF‐7 breast cancer

Bahmani

Dizaji

Talaei

et al. 2022

Polymers for Advanced Techs

Self Cite

View full text Add to dashboard Cite

In the present study, paclitaxel (PTX), multi‐walled carbon nanotubes (MWCNTs), and doxorubicin (DOX) have been simultaneously doped into the poly(ϵ‐caprolactone) (PCL)/chitosan/zein core‐shell nanofibers to increase its cytotoxicity for MCF‐7 breast cancers killing. The physico‐chemical properties of synthesized nanofibers were determined by scanning electron microscope, Fourier‐transform infrared spectroscopy, tensile strength, and degradation rate determinations. The in vitro release studies demonstrated the sustained release of drugs from core‐shell nanofibrous scaffold. The cytotoxicity and compatibility of core‐shell nanofibers were investigated by their treating with MCF‐7 breast cancer cells and L929 normal cells, respectively. PCL/PTX/chitosan/zein/MWCNTs/DOX core‐shell nanofibers containing 1 wt% MWCNTs, 100 μg ml−1 DOX and 100 μg ml−1 PTX had a high biocompatibility with a 84% MCF‐7 cancer cells killing. The in vivo studies revealed the synergic effects of MWCNTs and anticancer drugs on the tumor inhibition. This method could be considered as a new way for developing of MWCNTs loaded‐nanofibers for cancer treatment in future.

show abstract

PVA/κ-carrageenan/Au/camptothecin/pegylated-polyurethane/paclitaxel nanofibers against lung cancer treatment

Abstract: Core–shell nanofibers and in vivo release from core–shell nanofibers against lung cancer.

Cited by 10 publications

References 51 publications

Electrospun multi‐chamber core–shell nanofibers and their controlled release behaviors: A review

Electrospun multi‐chamber core–shell nanofibers and their controlled release behaviors: A review

Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy

Fabrication of poly(ϵ‐caprolactone)/paclitaxel (core)/chitosan/zein/multi‐walled carbon nanotubes/doxorubicin (shell) nanofibers against MCF‐7 breast cancer

Contact Info

Product

Resources

About